[Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].

In a prospective open study 16 consecutive patients with a myeloproliferative syndrome and thrombocytosis were treated with interferon (IFN) alpha-2a. 4 patients had polycythemia vera, 4 essential thrombocythemia, 3 myeloid metaplasia and 5 chronic granulocytic leukemia. Platelet counts decreased in all treated patients within 2 to 12 weeks from a median value of 1010 x 10(9)/l to 350 x 10(9)/l. No primary or secondary resistance was observed. The initial dose of IFN was 9 m U per day. After correction of the thrombocytosis, it was progressively reduced to a minimum dose of 3 m U per week. Despite the good platelet response to IFN, leukocytosis persisted in 3 patients and polycythemia in a further 3. Side effects and poor compliance required discontinuation of therapy in 6 patients. Special attention is focused on the follow-up in 6 patients who have been treated for more than 15 months.
AuthorsA Tichelli, A Gratwohl, F Delacrétaz, H Dazzi, C Stebler, M Wernli, E E Holdener, C Nissen, B Speck
JournalSchweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 119 Issue 39 Pg. 1347-52 (Sep 30 1989) ISSN: 0036-7672 [Print] SWITZERLAND
Vernacular TitleTherapie der Thrombozytose bei myeloproliferativen Syndromen mit rekombinantem Interferon-alpha-2a.
PMID2799342 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Interferon Type I
  • Interferon-alpha
  • Recombinant Proteins
  • interferon alfa-2a
  • Adult
  • Aged
  • Female
  • Humans
  • Interferon Type I (therapeutic use)
  • Interferon-alpha (adverse effects, therapeutic use)
  • Male
  • Middle Aged
  • Myeloproliferative Disorders (complications, therapy)
  • Pilot Projects
  • Prospective Studies
  • Recombinant Proteins
  • Thrombocytosis (etiology, therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: